Amarin’s New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes
New data shows that Amarin Corporation plc's (NASDAQ: AMRN) Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors.